Zoetis’ Apoquel Chewable Receives the US FDA’s Approval for Control of Pruritus Associated with Allergic Dermatitis and Control of Atopic Dermatitis in Dogs
Shots:
- The US FDA has approved Apoquel Chewable (oclacitinib chewable tablet) for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs aged ≥1yr.
- Zoetis continues to lead in dermatology innovation with a new formulation and shows after the first dosage comparable efficacy to that of Apoquel (oclacitinib tablet)
- In the US field test, 120 pet dogs received 1662 doses of Apoquel Chewable & an authorized dose range of 0.4-0.6mg/kg was given BID for ~14 days with the first 7 days of treatment used to assess palatability. The study discovered that a total of 1522 doses of Apoquel Chewable (91.6%) were freely accepted within 5min.
Ref: Zoetis | Image: Zoetis
Related News:- Zoetis’ Librela (bedinvetmab) Receives the US FDA’s Approval to Control Osteoarthritis Pain in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
